Onco360(R) , the nation's leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Corcept Therapeutics for LIFYORLI(TM) (relacorilant), which is indicated in ...

Corcept Therapeutics recently received U.S. FDA approval for Lifyorli (relacorilant) plus nab-paclitaxel to treat adults with platinum-resistant epithelial ovarian, fallopian tube, or primary ...

After collecting an FDA approval earlier this year for local pancreatic cancer, Novocure is putting forward positive clinical ...

Shares of Corcept Therapeutics (NASDAQ:CORT) surged about 40% on Wednesday after the U.S. Food and Drug Administration (FDA) ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...

A prospective, phase II, single-arm study of neoadjuvant/conversion therapy with camrelizumab, apatinib, S-1 ± oxaliplatin for locally advanced cT4a/bN+ gastric ...

Corcept Therapeutics CORT announced that the FDA has approved its selective glucocorticoid receptor antagonist, Lifyorli ...

FDA approval of Lifyorli plus nab-paclitaxel offers a new option for platinum-resistant epithelial ovarian cancer after 1 to 3 prior systemic regimens.

FDA authorization covers platinum-resistant disease after 1–3 prior lines, with mandatory prior bevacizumab exposure, ...

Recent advances in drug discovery research have led to the development of numerous drug candidate compounds with high ...

Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Corcept Therapeutics for LIFYORLI™ (relacorilant), which is indicated in ...